291 related articles for article (PubMed ID: 9784324)
1. Papillary serous and clear cell carcinoma limited to endometrial curettings in FIGO stage 1a and 1b endometrial adenocarcinoma: treatment implications.
Aquino-Parsons C; Lim P; Wong F; Mildenberger M
Gynecol Oncol; 1998 Oct; 71(1):83-6. PubMed ID: 9784324
[TBL] [Abstract][Full Text] [Related]
2. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
[TBL] [Abstract][Full Text] [Related]
3. The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation.
Jolly S; Vargas CE; Kumar T; Weiner SA; Brabbins DS; Chen PY; Floyd W; Martinez AA
Gynecol Oncol; 2006 Oct; 103(1):87-93. PubMed ID: 16545441
[TBL] [Abstract][Full Text] [Related]
4. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma.
Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
Gynecol Oncol; 1999 Sep; 74(3):385-94. PubMed ID: 10479498
[TBL] [Abstract][Full Text] [Related]
5. High-dose rate brachytherapy for Stage I/II papillary serous or clear cell endometrial cancer.
DuBeshter B; Estler K; Altobelli K; McDonald S; Glantz C; Angel C
Gynecol Oncol; 2004 Aug; 94(2):383-6. PubMed ID: 15297176
[TBL] [Abstract][Full Text] [Related]
6. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
Khalifa MA; Mannel RS; Haraway SD; Walker J; Min KW
Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788
[TBL] [Abstract][Full Text] [Related]
7. Endometrial carcinoma: the prognostic impact of papillary serous carcinoma (UPSC) in relation to nuclear grade, DNA ploidy and p53 expression.
Nordström B; Strang P; Lindgren A; Bergström R; Tribukait B
Anticancer Res; 1996; 16(2):899-904. PubMed ID: 8687148
[TBL] [Abstract][Full Text] [Related]
8. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
Gadducci A; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
Anticancer Res; 2000; 20(3B):1977-84. PubMed ID: 10928137
[TBL] [Abstract][Full Text] [Related]
9. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
Amant F; Cadron I; Fuso L; Berteloot P; de Jonge E; Jacomen G; Van Robaeys J; Neven P; Moerman P; Vergote I
Gynecol Oncol; 2005 Aug; 98(2):274-80. PubMed ID: 15972232
[TBL] [Abstract][Full Text] [Related]
10. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium.
Creasman WT; Kohler MF; Odicino F; Maisonneuve P; Boyle P
Gynecol Oncol; 2004 Dec; 95(3):593-6. PubMed ID: 15581969
[TBL] [Abstract][Full Text] [Related]
11. Accuracy of preoperative endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma.
Leitao MM; Kehoe S; Barakat RR; Alektiar K; Gattoc LP; Rabbitt C; Chi DS; Soslow RA; Abu-Rustum NR
Gynecol Oncol; 2008 Nov; 111(2):244-8. PubMed ID: 18752842
[TBL] [Abstract][Full Text] [Related]
12. Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion.
Orezzoli JP; Sioletic S; Olawaiye A; Oliva E; del Carmen MG
Gynecol Oncol; 2009 Jun; 113(3):316-23. PubMed ID: 19345400
[TBL] [Abstract][Full Text] [Related]
13. Management of aggressive histologic variants of endometrial carcinoma at the Tom Baker Cancer Centre between 1984 and 1994.
Craighead PS; Sait K; Stuart GC; Arthur K; Nation J; Duggan M; Guo D
Gynecol Oncol; 2000 May; 77(2):248-53. PubMed ID: 10785473
[TBL] [Abstract][Full Text] [Related]
14. [Uterine papillary serous carcinoma and papillary endometrial carcinoma: analysis of clinical biological behaviors of 56 cases].
Sun X; Shi S; Sheng X
Zhonghua Fu Chan Ke Za Zhi; 1996 Jan; 31(1):8-11. PubMed ID: 8758810
[TBL] [Abstract][Full Text] [Related]
15. Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study.
Sutton G; Axelrod JH; Bundy BN; Roy T; Homesley HD; Malfetano JH; Mychalczak BR; King ME
Gynecol Oncol; 2005 Jun; 97(3):755-63. PubMed ID: 15913742
[TBL] [Abstract][Full Text] [Related]
16. Minor serous and clear cell components adversely affect prognosis in ''mixed-type'' endometrial carcinomas: a clinicopathologic study of 36 stage-I cases.
Quddus MR; Sung CJ; Zhang C; Lawrence WD
Reprod Sci; 2010 Jul; 17(7):673-8. PubMed ID: 20393071
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences.
Soslow RA; Bissonnette JP; Wilton A; Ferguson SE; Alektiar KM; Duska LR; Oliva E
Am J Surg Pathol; 2007 Jul; 31(7):979-87. PubMed ID: 17592263
[TBL] [Abstract][Full Text] [Related]
18. Survival after stage IA endometrial cancer; can follow-up be altered? A prospective nationwide Danish survey.
Lajer H; Elnegaard S; Christensen RD; Ortoft G; Schledermann DE; Mogensen O
Acta Obstet Gynecol Scand; 2012 Aug; 91(8):976-82. PubMed ID: 22548255
[TBL] [Abstract][Full Text] [Related]
19. Early stage uterine papillary serous carcinoma of the endometrium: effect of adjuvant whole abdominal radiotherapy and pathologic parameters on outcome.
Lim P; Al Kushi A; Gilks B; Wong F; Aquino-Parsons C
Cancer; 2001 Feb; 91(4):752-7. PubMed ID: 11241243
[TBL] [Abstract][Full Text] [Related]
20. The significance of the amount of myometrial invasion in patients with Stage IB endometrial carcinoma.
Alektiar KM; McKee A; Lin O; Venkatraman E; Zelefsky MJ; Mychalczak BR; McKee B; Hoskins WJ; Barakat RR
Cancer; 2002 Jul; 95(2):316-21. PubMed ID: 12124832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]